Cargando…

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis

Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This analysis characterized the pharmacokinetics (PK) of tofacitinib in adult patients with active PsA and evaluated the impact of covariates (baseline characteristics) on the disposition of tofa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Rujia, Deng, Chenhui, Wang, Qiang, Kanik, Keith S., Nicholas, Timothy, Menon, Sujatha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704728/ https://www.ncbi.nlm.nih.gov/pubmed/31319908 http://dx.doi.org/10.5414/CP203516

Ejemplares similares

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
por: Nash, Peter, et al.
Publicado: (2018)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
por: Nash, Peter, et al.
Publicado: (2020)

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
por: Burmester, Gerd R., et al.
Publicado: (2020)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
por: Ly, Karen, et al.
Publicado: (2019)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
por: Leng, Xiaomei, et al.
Publicado: (2023)

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers
por: Menon, Sujatha, et al.
Publicado: (2016)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
por: Giles, Jon T, et al.
Publicado: (2021)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2023)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
por: Winthrop, Kevin L., et al.
Publicado: (2022)

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
por: Fleischmann, Roy, et al.
Publicado: (2016)

Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States
por: Bungey, George, et al.
Publicado: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
por: Ritchlin, Christopher T., et al.
Publicado: (2020)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
por: Todberg, Tanja, et al.
Publicado: (2020)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
por: Chen, Yang, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
por: Thakre, Neha, et al.
Publicado: (2022)

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
por: Strand, Vibeke, et al.
Publicado: (2015)

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
por: de Vlam, Kurt, et al.
Publicado: (2022)

Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
por: Gao, W, et al.
Publicado: (2016)

Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
por: Isaacs, John D, et al.
Publicado: (2014)

Effects of naringenin on the pharmacokinetics of tofacitinib in rats
por: Wang, Bo, et al.
Publicado: (2020)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
por: Coates, Laura C., et al.
Publicado: (2021)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
por: Mease, Philip J., et al.
Publicado: (2023)

Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
por: Taylor, Peter C., et al.
Publicado: (2021)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rccr2qo256itj8gcm1smbco80b